The body of research on the effectiveness of current<unk>  is promising, but limited. Complete or partial treatment response has been seen in 20-30% of patients in trials treated with 177Lu-DOTATATE or 90Y-DOTATOC, among the most widely used<unk>  drugs. When it comes to comparing these two<unk> , Y-labeled and Lu-labeled<unk> s, it appears that Y-labeled is more effective for larger tumors, while Lu-labeled is better for smaller and primary tumors. The lack of ɤ-emission with Y-labeled PPRTs is also an important difference between Lu<unk> s and Y<unk> . In particular, with Y-labeled<unk>  it becomes difficult to set up a dose of radiations specific to the patient's needs. In most cases<unk>  is used for cancers of the gastroenteropancreatic and bronchial tracts, and in some cases phaeochromocytoma, paraganglioma, neuroblastoma or medullary thyroid carcinoma. Various approaches to approve effectiveness and limit side effects are being investigated, including radiosensitising drugs, fractionation regimes and new<unk> s. Alpha emitters, which have much shorter ranges in tissue (limiting the effect on nearby healthy tissue), such as bismuth-213 or actinium-225 labelled DOTATOC are of particular interest.
Peptide receptor radionuclide therapy
Radionuclide therapy
Targeted therapy
Monoclonal antibody therapy
Fluoride therapy
Multisystemic therapy
Chemoimmunotherapy
Targeted alpha-particle therapy